Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imalux seeks to confirm OTC's (Optical coherence tomography) value in major EU bladder cancer trials:

This article was originally published in Clinica

Executive Summary

Optical coherence tomography (OCT) manufacturer Imalux has begun a series of European bladder cancer trials to support its technology's value in identifying the earliest signs of the disease. One German study, which will involve over 25,000 patients, will also assess the technology's use in preventing tumour recurrence and progression. The Cleveland, Ohio firm's Niris OTC imaging system, which is already cleared for sale in the US and Europe, will be used in the studies. According to the company, the "application of the proven OCT technology is on the verge of becoming the sixth major imaging modality".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel